<DOC>
	<DOC>NCT01231997</DOC>
	<brief_summary>This study is designed to assess the effect of renal impairment on the pharmacokinetics, safety and tolerability of udenafil in subjects with renal impairment compared to healthy subjects.</brief_summary>
	<brief_title>Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Adult males aged 19 to 64 years at screening. Subjects with body weight ≥ 55 kg and within ±30% of the ideal body weight : Ideal body weight = (height [cm] 100)x0.9. Subjects who have received and understood completely the information regarding the current study and given written informed consents to voluntarily participate in the study and followed all instructions specified in the protocol. Subjects with the test results of QTc &gt; 430 ms or nonsinus cardiac rhythm by ECG analysis. Subjects with hypotension or hypertension. Subjects who have drunken habitually (exceeding 21 units/week, 1 unit = 10 g of pure alcohol) or who are unable to abstain from drinking during the study period from 2 days prior to the first administration of investigational product and during this study. Subjects deemed ineligible by investigator based on other reasons, including abnormal laboratory values or diseases.</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Udenafil</keyword>
	<keyword>DA-8159</keyword>
	<keyword>renal impairment</keyword>
	<keyword>healthy volunteers</keyword>
</DOC>